Takeda Highlights Rare Neurological Disorder Programs In Wave 1
Company Already Has Pivoted Away From Larger Psychiatric Indications
Seeing significant unmet medical needs and insufficiently met needs in narcolepsy and rare types of epilepsy, Takeda has shifted its neuroscience focus.
You may also be interested in...
Revising the two companies’ 2017 epilepsy collaboration, Takeda will take over Phase III development and commercialization of soticlestat. Ovid gets $196m up front, and it can shift focus.
As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?
Entyvio strong again for Japanese firm as it raises net profit forecast on lower tax costs. Meanwhile, 'Wave 1' pipeline projects are progressing, with simultaneous development in major markets a key goal.